Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix is a promising biotechnology company specializing in innovative therapies for eye diseases, such as DEXTENZA, OTX-TIC, OTX-TKI, and OTX-IVT. Despite regulatory and commercial risks, financial risks, and intellectual property risks, Ocular has strong potential for market success, as evidenced by its current revenue-generating product and the potential of its portfolio of assets, including Axpaxli. With promising clinical data, a strong management strategy, and a focus on long-term sustainability through initiatives like the SOL-X OLE program, Ocular is well-positioned for growth and has a 12-month estimated market value of $5.46B.

Bears say

Ocular Therapeutix is a biotechnology company with a negative outlook based on its lack of revenue-generating products and heavy reliance on its lead asset, AXPAXLI, for future success. There are also financial and clinical risks associated with the potential failure of AXPAXLI in clinical trials or difficulties with commercialization. The success of AXPAXLI is also dependent on market growth and support from payors, and there is ongoing debate surrounding its potential commercial uptake and superiority over competitors.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.